P30 CATCH UP Above Accrual Goal Administrative Supplement Request

CCSG父摘要： 堪萨斯大学癌症中心(KUCC)是一个矩阵联盟癌症中心，包括： 堪萨斯大学医学中心(KUMC)、堪萨斯大学劳伦斯分校(KU-L)和VIA 财团协议，斯托尔斯医学研究所(斯托尔斯)和儿童慈善组织 (厘米)堪萨斯城。2020年，KUCC的171个成员提供了970万美元的NCI资金，总共 与癌症相关的资金总额为5700万美元，比上次CCSG提交的报告增加了800万美元。支撑点 在经验丰富的全国公认的领导团队的帮助下，医学博士Roy A.Jensen领导KUCC进行了一项 自2004年以来，超过4.67亿美元的慈善支持推动了强劲的上升轨迹。完毕 在过去四年中，在扩大与社区的伙伴关系方面取得了实质性进展 在整个KUCC集水区，招募高度创新的内科科学家，并扩大 临床研究和早期临床试验。我们也一直在推进下一阶段的教育 一代科学家和医疗保健提供者，并提高KUCC研究人员在 国家科学界。KUCC确立了五个目标，以确保KUCC在战斗中领先 抗癌： 1.利用独特的区域资产来转化实验室和 临床推动抗癌治疗新发展。 2.提供最优环境，集中精准医学、基础科学探究、 药物发现和开发，以及降低癌症发病率的行为干预， 发病率和死亡率。 3.领导和实施全面战略，教育当代和下一代 从事癌症研究、治疗、预防和控制的癌症研究人员和临床医生。 4.与主要利益攸关方、社区倡导者和地区领导人合作，制定、促进、 并促进以研究为基础的癌症预防、诊断、治疗、控制和生存 战略，以提高我们的国家影响力，改善癌症结果，并确保卫生公平。 5.通过培养创新的伙伴关系和合作来促进团队科学。 为了实现这些目标，KUCC有三个研究项目：1)癌症生物学，2)癌症 预防和控制，以及3)药物发现、传递和实验治疗。此外, KUCC支持临床试验办公室，七个已建立的共享资源-Biospecimen， 生物统计学和信息学、临床药理学、流式细胞术、铅开发和 优化，营养，转基因和基因打靶-以及一个正在开发的共享资源- 显微镜与分析成像。 迎头赶上： KUCC早期计划允许访问尖端、创新的早期临床试验 向包括服务不足/农村人口在内的结核病患者提供援助，以努力缩小#年的结果差距 癌症护理。这一补充将允许KUCC早期计划在#年继续这些努力 与我们的农村和服务不足的合作伙伴合作。

Parent Abstract of CCSG: The University of Kansas Cancer Center (KUCC) is a matrix consortium cancer center that includes: The University of Kansas Medical Center (KUMC), the University of Kansas in Lawrence (KU-L) and via consortium agreement, the Stowers Institute for Medical Research (Stowers) and Children’s Mercy (CM) Kansas City. In 2020, 171 members of KUCC accounted for $9.7M of NCI funding and a total of $57M in overall cancer-related funding, an increase of $8M since the last CCSG submission. Supported by an experienced, nationally recognized leadership team, Roy A. Jensen, MD, has led KUCC on a strong upward trajectory that has been catalyzed by over $467M philanthropic support since 2004. Over the last four years, substantial progress has been made broadening partnerships with communities throughout the KUCC catchment area, recruiting highly innovative physician-scientists, and expanding clinical research and early phase clinical trials. We have also been advancing education for the next generation of scientists and healthcare providers and heightening the influence of KUCC researchers in the national scientific community. KUCC has established five aims to ensure KUCC leads in the fight against cancer: 1. Leverage unique regional assets to transform research discoveries from the laboratory and the clinic to drive new anticancer therapeutic development. 2. Provide the optimal environment to focus the power of precision medicine, basic science inquiry, drug discovery and development, and behavioral interventions to decrease cancer incidence, morbidity, and mortality. 3. Lead and implement a comprehensive strategy to educate both the current and next generation of cancer researchers and clinicians in cancer research, treatment, prevention, and control. 4. Partner with key stakeholders, community advocates and regional leaders to develop, promote, and foster research-based cancer prevention, diagnosis, treatment, control, and survivorship strategies to enhance our national impact, improve cancer outcomes and ensure health equity. 5. Advance team science by fostering innovative partnerships and collaborations. To accomplish these aims KUCC has three research programs: 1) Cancer Biology, 2) Cancer Prevention and Control, and 3) Drug Discovery, Delivery and Experimental Therapeutics. In addition, KUCC supports the Clinical Trials Office, seven established shared resources – Biospecimen, Biostatistics and Informatics, Clinical Pharmacology, Flow Cytometry, Lead Development and Optimization, Nutrition, and Transgenic and Gene-Targeting – and one developing shared resource – Microscopy & Analytical Imaging. CATCH-UP: The KUCC Early Phase Program allows access to cutting edge, innovative, early phase clinical trials to pts including those in the underserved/rural population in an effort to reduce outcome disparity in cancer care. This supplement will allow the KUCC Early Phase Program to continue these efforts in collaboration with our rural and underserved partners.